Novus Therapeutics (NASDAQ:NVUS) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35), Bloomberg Earnings reports.
Shares of NVUS stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.80. The company’s stock had a trading volume of 17,181 shares, compared to its average volume of 108,038. Novus Therapeutics has a 52-week low of $0.71 and a 52-week high of $5.78. The company has a 50-day moving average of $0.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.18 and a current ratio of 3.18. The firm has a market capitalization of $10.39 million, a PE ratio of -0.51 and a beta of 2.87.
Several equities research analysts have commented on NVUS shares. Zacks Investment Research raised Novus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 28th. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $10.00 target price on shares of Novus Therapeutics in a report on Wednesday, May 15th. Finally, ValuEngine downgraded Novus Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, July 26th.
Novus Therapeutics Company Profile
Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.